🔗 Visit the ClinicalTrials.gov page for NCT00634270
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. | Neuro Oncol | 2014 | 1.66 |
| 2 | Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. | Best Pract Res Clin Endocrinol Metab | 2010 | 1.35 |
| 3 | Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. | Ther Drug Monit | 2013 | 0.83 |
| 4 | Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | J Transl Med | 2013 | 0.78 |
| 5 | Advances in paediatric cancer treatment. | Transl Pediatr | 2014 | 0.76 |
| 6 | Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants. | CPT Pharmacometrics Syst Pharmacol | 2016 | 0.75 |